SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sanda MG,Ayyagari SR,Jaffee EM. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol. 1994; 151: 622628.
  • 2
    Schlom J,Arlen PM,Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res. 2007; 13: 37763782.
  • 3
    Simons JW,Carducci MA,Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006; 12(11 pt 1): 33943401.
  • 4
    Small EJ,Schellhammer PF,Higano CS, et al. Placebo-controlledphase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24: 30893094.
  • 5
    Lin AM,Hershberg RM,Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006; 24: 434441.
  • 6
    Dipaola R,Plante M,Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006; 4: 1.
  • 7
    Simmons AD,Li B,Gonzalez-Edick M, et al. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother. 2007; 56: 16531665.
  • 8
    Small EJ,Sacks N,Nemunaitis J, et al. GM-CSF-secreting, allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007; 13: 38833891.
  • 9
    Jaffee EM,Hruban RH,Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001; 19: 145156.
  • 10
    Thomas AM,Santarsiero LM,Lutz ER, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004; 200: 297306.
  • 11
    Bubley GJ,Carducci M,Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 34613467. Erratum in: J Clin Oncol. 2000; 18: 2644.
  • 12
    Green S,Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992; 10: 239253.
  • 13
    Agresti A. Categorical Data Analysis, New York: John Wiley; 1990: 100102.
  • 14
    Kaplan EI,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457.
  • 15
    Halabi S,Small EJ,Kantoff PW, et al. Prognostic model for predicting survival in men with HRPC. J Clin Oncol. 2003; 21: 12321237.
  • 16
    Serafini P,Carbley R,Noonan KA,Tan G,Bronte V,Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004; 64: 63376343.
  • 17
    Tannock IF,de Wit R,Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 15: 15021512.
  • 18
    [Anonymous Author]. Leukine Sargramostim Package Insert, Revision 0230-03. Richmond, California: Berlex Laboratories; June 2002.
  • 19
    van der Flier A,Sonnenberg A. Structural and functional aspects of filamins. Biochim Biophys Acta. 2001; 1538: 99117.
  • 20
    Takafuta T,Wu G,Murphy GF,Shapiro SS. Human beta-filamin is a new protein that interacts with the cytoplasmic tail of glycoprotein Ibalpha. J Biol Chem. 1998; 273: 1753117538.
  • 21
    Sjoblom T,Jones S,Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314: 268274.